Skip to main contentSkip to main content
You have permission to edit this article.
top story

BD in Holdrege receives order for more than 1 billion injection devices to support COVID-19 vaccination efforts

  • 0

HOLDREGE — Becton, Dickinson and Company, a leading global medical technology company with a facility in Holdrege, recently announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to support global COVID-19 vaccination planning efforts.

This milestone reflects commitments from governments across the world, including the United States, Australia, Belgium, Canada, Germany, Netherlands, Saudi Arabia, Spain and the United Kingdom, among several others, as well as non-governmental organizations supporting vaccine deployment for developing countries.

Shipments are underway and more than 300 million injection devices have been delivered around the world so far with the remaining orders to be delivered between now and the end of 2021 to support vaccine administration. These devices are being shipped to governments or appointed distribution partners where they then will be distributed to health care facilities based on each country’s individual distribution and allocation strategy. BD continues to be in discussions with governments and non-governmental organizations on the need to place orders immediately for delivery later in calendar year 2021 and 2022.

“This milestone is more than just a number – it represents hundreds of millions of people around the world, such as frontline workers and at-risk loved ones who will now be able to receive a vaccination the moment vaccines are available,” said Rick Byrd, president of Medication Delivery Solutions for BD. “We recognize our manufacturing and supply chain teams who are working around the clock to make and deliver these essential devices throughout the world. From our decades of immunization experience, we also know our work doesn’t stop at delivery. We are equally committed to providing resources to ensure health care communities globally have the right training tools and support on injection techniques to implement these campaigns.”

The company continues to closely plan supply capabilities to ensure maximum volumes can be dedicated to COVID-19 efforts while minimizing disruption for routine health care and annual flu vaccination and childhood immunization programs.

In addition to supporting immediate efforts for COVID-19 vaccination readiness, BD also is working on multiple fronts to help ensure the global community is prepared for future pandemic vaccination efforts by:

- Partnering with the U.S. government on a $70 million capital project to further expand BD’s operations and manufacturing capacity in Nebraska, including Holdrege. The new capacity is expected to be online in summer 2021 and once completed, the federal government will have priority access to hundreds of millions of injection devices to support vaccination efforts for COVID-19 and future pandemics.

- Investing approximately $1.2 billion over a four-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems to allow for continued growth of new injectable drugs and vaccines, but also provide surge capacity for increased pre-fillable syringe demand during times of pandemic response.

- Actively engaging with med-tech associations and research groups to address challenges, solutions and further innovation in support of a more sustainable future vaccine ecosystem.

BD is the largest manufacturer of injection devices in the world, producing billions of syringes and needles annually through its global manufacturing network.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | Omny Studio

Get up-to-the-minute news sent straight to your device.


Breaking News